Sema4_Logo2021_Primary_Gradient.png
Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2022 16:05 ET | Sema4
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
May 02, 2022 07:45 ET | Sema4
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...
Sema4_Logo2021_Primary_Gradient.png
Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
April 26, 2022 16:05 ET | Sema4
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Achieves HITRUST CSF Certification
April 06, 2022 08:00 ET | Sema4
STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform,...
Sema4_Logo2021_Primary_Gradient.png
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
April 05, 2022 08:00 ET | Sema4
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
March 14, 2022 16:05 ET | Sema4
37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue...
Healthy Nevada Project
Childhood Trauma and Genetics Linked to Increased Obesity Risk
March 09, 2022 13:00 ET | Desert Research Institute
Reno, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- New research from the Healthy Nevada Project® found associations between genetics, obesity, and childhood trauma, linking social health determinants,...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
March 08, 2022 08:00 ET | Sema4
STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, has been named to Fast Company’s prestigious annual...
DH-Logo-LightBackgrounds.png
The Path to Seedless Cannabis: How Triploid Sterile Varieties Can Help Farmers Stop Worrying About Unwanted Pollen
February 24, 2022 17:34 ET | Dark Heart Industries
DAVIS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Dark Heart Nursery Executive Speaking Alert. What: Cutting-edge cannabis science content. Richard Philbrook, a leading expert on molecular biology,...
myriad_S_stacked.png
Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
February 24, 2022 09:00 ET | Myriad Genetics, Inc.
Highlights: Strong business performance despite COVID-19 headwindsRevenue of $160.8 million in the fourth quarter and $690.6 million for the year ended Dec. 31, 2021, up 4% and 24%, respectively...